Published in Mol Cell Biol on January 01, 2003
Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol (2009) 3.73
Using optogenetics to interrogate the dynamic control of signal transmission by the Ras/Erk module. Cell (2013) 2.22
Clinical relevance of KRAS in human cancers. J Biomed Biotechnol (2010) 1.34
Mechanism for fetal hemoglobin induction by histone deacetylase inhibitors involves gamma-globin activation by CREB1 and ATF-2. Blood (2006) 1.27
Identification of functional modules that correlate with phenotypic difference: the influence of network topology. Genome Biol (2010) 1.25
STAT3 negatively regulates thyroid tumorigenesis. Proc Natl Acad Sci U S A (2012) 1.23
Noncatalytic function of ERK1/2 can promote Raf/MEK/ERK-mediated growth arrest signaling. J Biol Chem (2009) 1.18
Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J Clin Invest (2004) 1.07
Aberrant gene expression in mucosa adjacent to tumor reveals a molecular crosstalk in colon cancer. Mol Cancer (2014) 1.00
Development of a malignancy-associated proteomic signature for diffuse large B-cell lymphoma. Am J Pathol (2009) 0.94
The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells. Exp Cell Res (2011) 0.93
A novel U-STAT3-dependent mechanism mediates the deleterious effects of chronic nicotine exposure on renal injury. Am J Physiol Renal Physiol (2011) 0.91
Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo. J Clin Endocrinol Metab (2013) 0.91
Growth arrest signaling of the Raf/MEK/ERK pathway in cancer. Front Biol (Beijing) (2014) 0.90
Regulation and function of trefoil factor family 3 expression in the biliary tree. Am J Pathol (2004) 0.90
Three LIF-dependent signatures and gene clusters with atypical expression profiles, identified by transcriptome studies in mouse ES cells and early derivatives. BMC Genomics (2009) 0.88
A Key Role for Leukemia Inhibitory Factor in C26 Cancer Cachexia. J Biol Chem (2015) 0.86
Transforming growth factor-{beta} coordinately induces suppressor of cytokine signaling 3 and leukemia inhibitory factor to suppress osteoclast apoptosis. Endocrinology (2010) 0.86
Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells. Oncogene (2014) 0.85
Multi-targeted approach in the treatment of thyroid cancer. Ther Clin Risk Manag (2008) 0.85
Mouse mammary tumors display Stat3 activation dependent on leukemia inhibitory factor signaling. Breast Cancer Res (2007) 0.84
Recombinant leukemia inhibitory factor suppresses human medullary thyroid carcinoma cell line xenografts in mice. Cancer Lett (2013) 0.83
Exogenous leukemia inhibitory factor (LIF) attenuates retinal vascularization reducing cell proliferation not apoptosis. Exp Eye Res (2006) 0.83
Leukemia inhibitory factor in rat fetal lung development: expression and functional studies. PLoS One (2012) 0.82
Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma. Int J Endocrinol (2013) 0.81
Medullary thyroid carcinoma: targeted therapies and future directions. J Oncol (2009) 0.81
Comparison of epigenetic profiles of human oral epithelial cells from HIV-positive (on HAART) and HIV-negative subjects. Epigenetics (2013) 0.80
The Role of STAT3 in Thyroid Cancer. Cancers (Basel) (2014) 0.80
Phosphoinositide and Erk signaling pathways mediate activity-driven rodent olfactory sensory neuronal survival and stress mitigation. J Neurochem (2015) 0.80
Tumor suppressor role of notch1 and raf-1 signaling in medullary thyroid cancer cells. Transl Oncogenomics (2007) 0.79
Signaling mechanisms in neuroendocrine tumors as targets for therapy. Endocrinol Metab Clin North Am (2010) 0.78
Focal adhesion kinase, a downstream mediator of Raf-1 signaling, suppresses cellular adhesion, migration, and neuroendocrine markers in BON carcinoid cells. Mol Cancer Res (2010) 0.78
Tumour cells expressing single VEGF isoforms display distinct growth, survival and migration characteristics. PLoS One (2014) 0.77
Selective Mitochondrial Uptake of MKT-077 Can Suppress Medullary Thyroid Carcinoma Cell Survival In Vitro and In Vivo. Endocrinol Metab (Seoul) (2015) 0.77
The difference in biological properties between parental and v-Ha-ras transformed NIH3T3 cells. Cancer Res Treat (2009) 0.77
LIF upregulates expression of NK-1R in NHBE cells. Mediators Inflamm (2006) 0.77
Neural stem cells secrete factors facilitating brain regeneration upon constitutive Raf-Erk activation. Sci Rep (2016) 0.75
High LIFr expression stimulates melanoma cell migration and is associated with unfavorable prognosis in melanoma. Oncotarget (2015) 0.75
The teratogenicity and the action mechanism of gallic acid relating with brain and cervical muscles. PLoS One (2015) 0.75
KRASG12 mutant induces the release of the WSTF/NRG3 complex, and contributes to an oncogenic paracrine signaling pathway. Oncotarget (2016) 0.75
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell (1997) 29.13
A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A (1998) 24.58
Stat3 as an oncogene. Cell (1999) 17.39
Creation of human tumour cells with defined genetic elements. Nature (1999) 16.47
Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF). EMBO J (1987) 7.45
Regulation of the G2/M transition by p53. Oncogene (2001) 7.02
A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry (1983) 6.38
Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev (1998) 5.14
The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol (2001) 4.83
Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science (1993) 4.76
Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol (1997) 4.36
Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol (1998) 3.61
Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human raf-1 protein kinase. Mol Cell Biol (1993) 3.13
High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol (1997) 2.89
Fibroblast immortality is a prerequisite for transformation by EJ c-Ha-ras oncogene. Nature (1983) 2.77
p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev (2000) 2.74
Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ (1997) 2.63
Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. Genes Dev (2000) 2.62
Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev (2001) 2.56
In vitro establishment is not a sufficient prerequisite for transformation by activated ras oncogenes. Cell (1986) 2.13
Cooperating oncogenes converge to regulate cyclin/cdk complexes. Genes Dev (1997) 1.88
The cat and mouse games that genes, viruses, and cells play. Cell (1997) 1.85
Ras-mediated cell cycle arrest is altered by nuclear oncogenes to induce Schwann cell transformation. EMBO J (1988) 1.80
Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes. Genes Dev (1995) 1.79
The cytoplasmic raf oncogene induces a neuronal phenotype in PC12 cells: a potential role for cellular raf kinases in neuronal growth factor signal transduction. Proc Natl Acad Sci U S A (1993) 1.63
Raf-1 causes growth suppression and alteration of neuroendocrine markers in DMS53 human small-cell lung cancer cells. Am J Respir Cell Mol Biol (1999) 1.58
Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein kinase B and p70 S6 kinase phosphorylation in cardiac myocytes. J Biol Chem (1998) 1.52
Nerve growth factor induces survival and differentiation through two distinct signaling cascades in PC12 cells. Oncogene (1999) 1.41
Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15(INK4b). Mol Cell Biol (2000) 1.41
STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells . Prostate (2000) 1.40
Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol (1993) 1.37
Ceramide-binding and activation defines protein kinase c-Raf as a ceramide-activated protein kinase. Proc Natl Acad Sci U S A (1996) 1.34
Mitogenic conversion of transforming growth factor-beta1 effect by oncogenic Ha-Ras-induced activation of the mitogen-activated protein kinase signaling pathway in human prostate cancer. Cancer Res (2000) 1.33
Raf-1-induced growth arrest in human mammary epithelial cells is p16-independent and is overcome in immortal cells during conversion. Oncogene (2002) 1.32
Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. Endocr Rev (2000) 1.28
Oncogenic Ras induces p19ARF and growth arrest in mouse embryo fibroblasts lacking p21Cip1 and p27Kip1 without activating cyclin D-dependent kinases. J Biol Chem (2000) 1.20
Introduction of v-Ha-ras oncogene induces differentiation of cultured human medullary thyroid carcinoma cells. Proc Natl Acad Sci U S A (1987) 1.20
Leukemia inhibitory factor modulates interleukin-1beta-induced activation of the hypothalamo-pituitary-adrenal axis. Endocrinology (1998) 1.19
STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate (2000) 1.19
Activated Raf-1 causes growth arrest in human small cell lung cancer cells. J Clin Invest (1998) 1.17
Raf-1-induced cell cycle arrest in LNCaP human prostate cancer cells. J Cell Biochem (1999) 1.03
Activation of signal transducers and activators of transcription 1 and 3 by leukemia inhibitory factor, oncostatin-M, and interferon-gamma in adipocytes. J Biol Chem (1998) 1.03
Ret gene silencing is associated with Raf-1-induced medullary thyroid carcinoma cell differentiation. Cancer Res (1995) 1.02
Critical role for STAT3 in murine pituitary adrenocorticotropin hormone leukemia inhibitory factor signaling. J Biol Chem (1999) 1.00
p19ARF-independent induction of p53 and cell cycle arrest by Raf in murine keratinocytes. EMBO Rep (2001) 0.98
Regulation of the p53 pathway by Ras, the plot thickens. Biochim Biophys Acta (2001) 0.98
Leukemia inhibitory factor and its receptor promote adipocyte differentiation via the mitogen-activated protein kinase cascade. J Biol Chem (1999) 0.96
Characterization of the interleukin-4 nuclear activated factor/STAT and its activation independent of the insulin receptor substrate proteins. J Biol Chem (1995) 0.96
p53 tumor-suppressor gene: clues to molecular carcinogenesis. J Cell Physiol (1997) 0.93
Mechanisms that uncouple growth and differentiation in myeloid leukemia cells: restoration of requirement for normal growth-inducing protein without restoring induction of differentiation-inducing protein. Proc Natl Acad Sci U S A (1982) 0.92
Dual growth arrest pathways in astrocytes and astrocytic tumors in response to Raf-1 activation. J Biol Chem (2001) 0.89
Combined effects of aberrant MEK1 activity and BCL2 overexpression on relieving the cytokine dependency of human and murine hematopoietic cells. Leukemia (2000) 0.87
Involvement of protein kinase C during activation of the mitogen-activated protein kinase cascade by leukemia inhibitory factor. Evidence for participation of multiple signaling pathways. J Biol Chem (1994) 0.87
Raf-induced transformation requires an interleukin 1 autocrine loop. Cancer Res (2001) 0.84
Post-transcriptional silencing of RET occurs, but is not required, during raf-1 mediated differentiation of medullary thyroid carcinoma cells. Oncogene (1998) 0.83
Activation of acidic sphingomyelinase and protein kinase C zeta is required for IL-1 induction of LIF mRNA in a Schwann cell line. Glia (1996) 0.81
Leukemia inhibitory factor induces apoptosis and proliferation of human carcinoma cells through different oncogene pathways. Int J Cancer (1997) 0.80
The levels of leukemia inhibitory factor mRNA in a Schwann cell line are regulated by multiple second messenger pathways. J Neurochem (1999) 0.80
Signal transduction. Why Ras needs Rho. Nature (1998) 0.80
Effects of inducible MEK1 activation on the cytokine dependency of lymphoid cells. Leukemia (2001) 0.79
Prolongation by differentiation-stimulating factor/leukemia inhibitory factor of the survival time of mice implanted with mouse myeloid leukemia cells. Leuk Res (1992) 0.77
Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell (2003) 5.36
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31
Notch inhibits Ptf1 function and acinar cell differentiation in developing mouse and zebrafish pancreas. Development (2004) 2.21
Thyroid carcinoma. J Natl Compr Canc Netw (2010) 2.02
Notch in lung development and lung cancer. Semin Cancer Biol (2004) 1.73
Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab (2007) 1.66
Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res (2006) 1.65
Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. Cancer Res (2009) 1.55
Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer Res (2010) 1.54
Notch signaling induces rapid degradation of achaete-scute homolog 1. Mol Cell Biol (2002) 1.51
Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab (2005) 1.39
Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab (2009) 1.38
NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw (2009) 1.24
Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab (2012) 1.21
Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther (2011) 1.18
Thyroid carcinoma. J Natl Compr Canc Netw (2007) 1.13
Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. Clin Cancer Res (2011) 1.13
The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biol Ther (2010) 1.12
Clinical review: Incidentally discovered medullary thyroid cancer: diagnostic strategies and treatment. J Clin Endocrinol Metab (2011) 1.11
Thyroid carcinoma. J Natl Compr Canc Netw (2005) 1.04
DeltaNp63alpha overexpression induces downregulation of Sirt1 and an accelerated aging phenotype in the mouse. Cell Cycle (2006) 1.00
Insights into the achaete-scute homolog-1 gene (hASH1) in normal and neoplastic human lung. Lung Cancer (2012) 0.98
Medullary carcinoma. J Natl Compr Canc Netw (2010) 0.97
CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res (2003) 0.96
IFI16 is an essential mediator of growth inhibition, but not differentiation, induced by the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. J Biol Chem (2004) 0.96
Interleukin-1beta can mediate growth arrest and differentiation via the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. Cytokine (2004) 0.92
Misidentification of putative medullary thyroid cancer cell lines RO-H85-1 and RO-D81-1. J Clin Endocrinol Metab (2013) 0.92
American Thyroid Association guidelines for management of medullary thyroid cancer: an adult endocrinology perspective. Thyroid (2009) 0.89
Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits. J Biomol Screen (2010) 0.88
The homeobox gene BARX2 can modulate cisplatin sensitivity in human epithelial ovarian cancer. Int J Oncol (2002) 0.86
Selectively targeting mutant BRAF in thyroid cancer. J Clin Endocrinol Metab (2010) 0.85
GDNF-induced leukemia inhibitory factor can mediate differentiation via the MEK/ERK pathway in pheochromocytoma cells derived from nf1-heterozygous knockout mice. Exp Cell Res (2005) 0.83
Notch in malignancy. Cancer Treat Res (2003) 0.82
Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. J Clin Endocrinol Metab (2005) 0.82
Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2. Assay Drug Dev Technol (2010) 0.82
Cellular systems biology profiling applied to cellular models of disease. Comb Chem High Throughput Screen (2009) 0.81
Unusual case of metastatic neuroendocrine tumor. Endocr Pract (2007) 0.79
Anaplastic Thyroid Carcinoma, Version 2.2015. J Natl Compr Canc Netw (2015) 0.78
Toxicity assessments of nonsteroidal anti-inflammatory drugs in isolated mitochondria, rat hepatocytes, and zebrafish show good concordance across chemical classes. Toxicol Appl Pharmacol (2013) 0.78
High-content positional biosensor screening assay for compounds to prevent or disrupt androgen receptor and transcriptional intermediary factor 2 protein-protein interactions. Assay Drug Dev Technol (2014) 0.77
Serendipity in the diagnosis of pheochromocytoma. J Comput Assist Tomogr (2013) 0.75
High content screening biosensor assay to identify disruptors of p53-hDM2 protein-protein interactions. Methods Mol Biol (2015) 0.75
Assays for raf-1 kinase phosphorylation and activity in human small cell lung cancer cells. Methods Mol Med (2003) 0.75